26.10.2016 • NewsElaine BurridgecabotApplications

Cabot Expands Belgian Formulations Capacity

US specialty chemicals and performance materials company Cabot is investing an undisclosed sum in new capacity at its plant in Pepinster, Belgium. The project will enhance production capabilities for plastic formulations, specifically for conductive compounds and masterbatches used in engineering thermoplastic applications.

“We expect recent growth trends to continue, especially in automotive applications, given macro trends such as lightweighting and the need for our customers to innovate in ways that reduce overall costs, said Aaron Johnson, Cabot’s vice president for specialty compounds, Europe, Middle East & Africa and Americas.

The Boston, Massachusetts-headquartered company said the planned investment will also enable it to expand into additional (unspecified) applications. Cabot said it is the only globally integrated carbon black and black masterbatch producer. The company is the world’s second largest producer of carbon black in output terms, behind India’s Aditya Birla.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.